{
  "docId": "019de073-e290-7736-8636-bb9f9140da9a",
  "docSlug": "1f39d5e7324d630af88fbb56e2fd7037",
  "documentTitle": "AbCellera | Results Presentation Deck | 14 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 14,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a two-column layout to contrast two distinct proprietary platforms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e290-7736-8636-bb9f9140da9a/6",
  "deckHref": "/decks/019de073-e290-7736-8636-bb9f9140da9a",
  "deckJsonHref": "/decks/019de073-e290-7736-8636-bb9f9140da9a.json",
  "deckAnchorHref": "/decks/019de073-e290-7736-8636-bb9f9140da9a#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.38,
        "x": 0.11,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "T-Cell Engager Platform: Hundreds of diverse CD3-binding antibodies to combine to create optimized precision cancer therapies. Clinically-validated OrthoMab bispecifics platform. Internal validation on three well-recognized and high-value targets.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49697659-fe18-42bc-aeca-9161dc39ce37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.38,
        "x": 0.54,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "GPCRs & Ion Channels Platform: Clinically validated, membrane-protein targets with large commercial potential that have proven largely intractable using traditional methods. Integrated data science and biotechnology to generate best-in-class candidates.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee686ef1-585f-4395-ac7e-2debbab029b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.84,
        "x": 0.08,
        "y": 0.13
      },
      "kind": "title",
      "text": "UNRIVALED ABILITY TO BREAK THE BARRIERS OF CONVENTIONAL DRUG DISCOVERY.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bb55b40-616d-4e25-9e0c-4baf8b28cba0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.08,
        "y": 0.06
      },
      "kind": "title",
      "text": "PRE-PARTNERED PROGRAMS. CREATING VALUE THROUGH TECHNOLOGY-DEVELOPMENT.",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c36a92f-2f38-4543-9042-55a1efac2bcc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "32fe4f57-76e5-4951-92cc-e1b47527d767",
      "evidence": "The components mention specific programs and technologies, indicating a targeted audience.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "b77b7721-de6d-4467-8f65-229167456bc3",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "What Could Be",
      "beatSlug": "sparkline-what-could-be-2",
      "evidence": "Slides 4-6 highlight the company's capabilities and value proposition.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3d8f0e95-83ac-4d46-b5ab-06fbd46ffda6",
      "evidence": "Slides 4-6 implicitly suggest that not leveraging AbCellera's capabilities could hinder innovation.",
      "position": 0,
      "objective": "Emphasize the benefits of AbCellera's capabilities in drug discovery",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}